CARANX-MEDICAL
16.4.2024 10:31:35 CEST | Business Wire | Press release
Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal.
The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team.
“This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx.
“This major medical first lies not only in the technical achievement of Caranx Medical's engineers, but also in the impact that this technology will have on interventional cardiology practice. By simplifying and standardizing a complex procedure, the robot we have developed opens up new possibilities for improving the performance and safety of TAVI procedures” says Dr. Eric Sejor, co-founder and CMO of Caranx.
The TAVI procedure was introduced app. 20 years ago, and still critical challenges and long learning curves are faced by cardiologists during these procedures in a precise and accurate delivery of the heart valve. This is resulting in only 300.000 TAVI procedures being conducted annually in the USA and EU, despite over 1.700.000 eligible patients and the difficulty of the procedure still triggers some drawbacks like frequent need for post procedure pacemakers, due to a lack of precision in the delivery of the implant.
"It is with logic that we prove, and with intuition that we find". “This quote from Henri Poincaré perfectly sums up the work of the Caranx team, who had the intuition, that robotics combined with artificial intelligence and imaging could improve the results of prosthetic heart valve implantation. During this first robotic implantation on a porcine model, the sensations were very similar to those observed during a conventional procedure on our patients. There is no doubt that the use of robotics coupled with artificial intelligence and imaging will improve the safety, precision and reproducibility of the procedure in humans” says Dr. Stéphane Lopez, Institut Arnault Tzanck, Saint Laurent du var, France, who performs more than 400 TAVI procedures per year.
“The team at Caranx, has achieved an important milestone as it successfully deployed a balloon-expandable device in the aortic position, in a pig model. This extremely promising step paves the way to a first-in-human utilization. I am very excited about robotic-assisted TAVI/TAVR, a key to the harmonization of practices as well as the promotion of more predictable and controlled valve deployment. Our patients will undoubtedly benefit from this breakthrough technology in the future” says Dr. Didier Tchétché, Clinique Pasteur, Toulouse, France, who performs more than 1.000 TAVI procedures per year.
According to Frost and Sullivan, the TAVI market is an $8Bn market growing double digits annually.
“With Caranx impressive technology and team, interventional cardiology and physicians can hope for what aircrafts and pilots have been benefiting from for decades: reliable automation, supervised by pilots, imaging and AI for medicine mimicking satellite/GPS systems for flying” says Dr. Philippe Pouletty, co-founder of Caranx and CEO of Truffle Capital.
The Caranx Medical robotic solution, TAVI-PILOT, is a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. TAVI-PILOT is a revolution for the replacement of the aortic valve, which is restricted because it is reserved for the most experienced cardiologists. Like soft tissue robots have multiplied the number of urologists comfortable to execute a mini-invasive surgical removal of the prostate, TAVI-PILOT will multiply the number of interventional cardiologists to perform safely this life saving procedure.
“This is a major achievement by the Caranx team in the past months. However, at Caranx Medical, we're not just stopping at Aortic valve replacement. Our vision extends to developing our Artificial Intelligence Platform, currently containing more than 5000 of annotated multimodality images of CT, Fluoroscopy, Echo, reports, etc. used to feed our AI algorithms and to revolutionize other endovascular indications, such as mitral and tricuspid valve replacements or even other endoluminal procedures, reshaping the landscape of interventional medicine” says CEO of Caranx, Jorgen Hansen.
About Caranx Medical
Backed by a team of top-tier experts, management team and supported by Truffle Capital, a renowned name in European biotech and MedTech investment, Caranx Medical is a French MedTech company, founded by CMO Dr. Eric Sejor, CTO Pierre Berthet-Rayne, PhD. and Dr. Philippe Pouletty and Truffle Capital, with the ambition to become a global leader in robotic assisted transcatheter heart valve implantation.
Caranx Medical develops the TAVI PILOT, a simple, easy-to-use robotic solution, which promises precise, accurate and autonomous valve positioning and delivery. Caranx Medical’s strategy includes bringing to market TAVI PILOT Soft, an AI intra-operative GPS software which tracks real-time anatomical and instrument landmarks on fluoroscopic images and TAVI PILOT Robotic solution to First in Human in 2025.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416108426/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom